Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Ran, Qiqi [1 ]
Gan, Qianrong [1 ]
Zhu, Ye [2 ]
Song, Li [1 ]
Shen, Longyu [1 ]
Duan, Xinyi [1 ]
Zhu, Xinyun [3 ]
Huang, Wei [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Peoples R China
[2] Hainan Med Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Hainan 570102, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China
基金
美国国家科学基金会;
关键词
Non-alcoholic fatty liver disease; Nobiletin; Lipid metabolism; Insulin resistance; Anti-inflammatory; Anti-oxidation; CITRUS FLAVONOIDS; OXIDATIVE STRESS; PATHOGENESIS; CHOLESTEROL; INFLAMMATION; METABOLITES; INSULIN; CELLS; 4'-DEMETHYLNOBILETIN; 5-DEMETHYLNOBILETIN;
D O I
10.1016/j.biopha.2024.116322
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NOB) is the critical active ingredient of Chinese herbal medicines such as Citrus aurantium and Citri Reticulatae Pericarpium, which have antiinflammatory, antioxidant, lipid regulating, and insulin resistance regulating effects. Numerous studies have demonstrated that NOB can prevent and treat the onset and progression of NAFLD. In this review, the mechanisms of NOB for treating NAFLD have been summarized, hoping to provide a basis for subsequent studies of NOB and to provide a research ground for the development of therapeutic drugs for NAFLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease
    Qiu, Longxin
    Guo, Chang
    CURRENT DRUG TARGETS, 2020, 21 (06) : 599 - 609
  • [22] Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
    Musso, Giovanni
    Gambino, Roberto
    Cassader, Maurizio
    PROGRESS IN LIPID RESEARCH, 2009, 48 (01) : 1 - 26
  • [23] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    不详
    GASTROENTEROLOGE, 2021, 16 (05): : 386 - 386
  • [24] A lipidomic analysis of non-alcoholic fatty liver disease (NAFLD)
    Puri, P.
    Baillie, R. A.
    Wiest, M.
    Mirshahi, F.
    Sanyal, A. J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S260 - S261
  • [25] Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Drzewoski, Jozef
    Szymczak-Pajor, Izabela
    Zieleniak, Andrzej
    Mikolajczyk-Solinska, Melania
    Kasznicki, Jacek
    Sliwinska, Agnieszka
    BIOMEDICINES, 2022, 10 (09)
  • [26] Antiepileptic drugs and non-alcoholic fatty liver disease (NAFLD)
    Waldmann, M
    Sturm, W
    Naser, A
    Unterberger, I
    Trinka, E
    Bauer, G
    Lechleitner, M
    Luef, G
    EPILEPSIA, 2004, 45 : 161 - 162
  • [27] Diagnosis and management of non-alcoholic fatty liver disease (NAFLD)
    Byrne, C. D.
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A2 - A2
  • [28] Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Rong, Li
    Zou, Junyan
    Ran, Wei
    Qi, Xiaohong
    Chen, Yaokai
    Cui, Hongjuan
    Guo, Jinjun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [29] Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
    Tomasiewicz, Krzysztof
    Flisiak, Robert
    Halota, Waldemar
    Jaroszewicz, Jerzy
    Lebensztejn, Dariusz
    Lisik, Wojciech
    Malkowski, Piotr
    Pawlowska, Malgorzata
    Piekarska, Anna
    Simon, Krzysztof
    Tronina, Olga
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 4 (03) : 153 - 157
  • [30] Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
    Park, Yongsoo
    Ko, Kyung Soo
    Rhee, Byoung Doo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)